NCIC CTG CE.6/TROG 08.02 - GBM in Elderly Patients

By w.paterson
15 August, 2021
0 Comments

A Randomised Phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients.

Primary Sponsor

NCIC Clinical Trials Group (NCIC CTG)

Tour de Cure grants for TROG Cancer Research trials

9 January, 2025

Tour de Cure grants support two valuable TROG trials

9 January 2025: Two important TROG Cancer Research trials

7 January, 2025

GenesisCare Foundation $300,000 donation to support TROG work

7 January 2025: TROG Cancer Research is advancing vital

Earlybird registration closes 26 January.

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Randomised Phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients.

TROG 04.02 – Cervical – FIGO Stage & Tumour Volume

AGITG/TROG 21.03 – RESOLUTE

Related Post

Tour de Cure grants support two valuable TROG trials

GenesisCare Foundation $300,000 donation to support TROG work

NCIC CTG CE.6/TROG 08.02 – GBM in Elderly Patients

A Randomised Phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients.

TROG 04.02 – Cervical – FIGO Stage & Tumour Volume

AGITG/TROG 21.03 – RESOLUTE

Related Post

Tour de Cure grants support two valuable TROG trials

GenesisCare Foundation $300,000 donation to support TROG work